Bags and Tubing: Worst-Case Selection for SUS Manifolds

Published on 10/12/2025

Bags and Tubing: Worst-Case Selection for SUS Manifolds

The pharmaceutical industry is increasingly embracing single-use systems (SUS) for their flexibility and efficiency. However, the validation of materials such as bags and tubing is critical to ensure safety and compliance with regulatory frameworks. This comprehensive guide will provide a step-by-step tutorial on the worst-case selection for SUS manifolds concerning extractables and leachables (E&L), analytical evaluation thresholds (AET), dose-based thresholds (DBT), and container closure integrity (CCI). All practices are presented under the scrutiny of US FDA, EU GMP Annex 1, and other pertinent guidelines.

Understanding Extractables and Leachables (E&L)

Extractables and leachables are chemical substances that can migrate from packaging systems or components into pharmaceutical products, raising safety concerns primarily focused on patient health and product integrity. It is essential to understand the E&L risk assessment process before proceeding with SUS manifolds.

Common terminology used in the E&L process includes:

  • Extractables: Substances that can be extracted from packaging under aggressive conditions, typically analyzed in a controlled laboratory setting.
  • Leachables: Substances that migrate into the drug product under normal storage and use conditions.
  • Analytical Evaluation Threshold (AET): The minimum concentration at which a leachable can be reliably detected.
  • Dose-Based Threshold (DBT): This is based on actual exposure levels, which help to determine acceptable limits of leachables.

Understanding these terms is pivotal for informed decision-making regarding container and closure systems used in pharmaceutical operations.

Step 1: Regulatory Framework Compliance

Before commencing any validation procedure, familiarize yourself with relevant regulatory expectations. For US-based operations, compliance with FDA guidelines is paramount, particularly FDA process validation requirements. In the European context, look into the EU GMP Annex 1 which outlines the necessary expectations for sterile medicinal products. Familiarity with the PQRI guidelines also provides insights into best practices regarding packaging and materials.

Each governing body outlines responsibilities for stakeholders throughout the supply chain, expecting robust documentation and justification for all decisions made regarding E&L and validation procedures.

Step 2: Identification of Material Risks

The selection of bags and tubing for SUS manifolds involves assessing material risks. Consider the following factors:

  • Material Composition: Understand the polymeric makeup of the bags and tubing. Various resins will display different E&L profiles.
  • Manufacturing Processes: Evaluate processes such as extrusion, molding, and sterilization that could influence E&L properties.
  • Usage Conditions: Define the operational parameters, including storage temperature, duration, and process cycles.

Conduct a thorough E&L risk assessment to document potential material risks. This assessment will justify your worst-case selection of materials.

Step 3: Performing Worst-Case Selection

The worst-case selection process involves identifying materials that present the highest risk potential. When selecting bags and tubing, follow these steps:

3.1 Collect Comparative Data

Gather data from existing studies or supplier data regarding E&L profiles. Focus on the below parameters:

  • Extractables data under aggressive conditions.
  • Leachables profiles under normal usage conditions across multiple batches.

3.2 Determine AET and DBT

Calculate both the AET and DBT to set acceptable limits for leachables. Refer to established guidelines for establishing these thresholds. The USP USP stipulates criteria for conducting analytical assessments.

3.3 Choose the Worst-Case Scenario

Select the materials with the highest E&L profiles as your worst-case scenario. Document your rationale, highlighting data points and evaluation methods employed.

Step 4: Analytical Testing of Selected Materials

Once you have identified the worst-case materials, it is time to proceed with analytical testing. Follow these key steps:

4.1 Test Preparation

Prepare your samples according to standardized methodologies. Ensure that the extraction and leaching conditions reflect worst-case scenarios (e.g., increased temperatures, extended times).

4.2 Extraction Studies

Conduct extraction studies to quantify extractables. Common solvents may include water, ethanol, and hexane. Record all data and ensure analytical methods such as gas chromatography-mass spectrometry (GC-MS) and high-performance liquid chromatography (HPLC) are suitable for detection.

4.3 Leachable Studies

After the extraction phase, perform leachable studies on the drug product in contact with the materials under realistic conditions. Again, apply robust analytical techniques to measure leachables.

Step 5: Evaluation and Documentation

Upon completing analytical studies, the next step is to evaluate the findings:

5.1 Data Analysis

Evaluate the amassed data against AET and DBT values set earlier. Identify any leachables exceeding acceptable limits and document their potential impact on product safety.

5.2 Risk Management

In instances of identified risks, a detailed risk management plan must be developed. This may include modifications to material selections or additional studies to further refine material safety.

5.3 Documentation Practices

Ensure all data is meticulously documented, including methodologies used, results evaluated, and justifications made throughout the process. Good documentation practices (GDP) are critical not just for regulatory compliance, but also to facilitate understanding among stakeholders at all levels.

Step 6: Container Closure Integrity (CCI) Assessment

Concurrent with E&L studies, evaluate the integrity of the container closure systems to prevent product contamination and ensure compliance with USP CCI requirements. Integrate the following strategies in your CCI assessment:

6.1 Design and Material Verification

Verify that the selected bags and tubing provide adequate barrier properties. Assess the manufacturing consistency of these materials.

6.2 CCI Testing

Conduct testing methods such as vacuum decay, bubble tests, or dye penetration tests. The chosen methods should reflect the intended use of the packaging system.

Conclusion: Maintaining Compliance and Safety

In summary, the proper selection and validation of bags and tubing for single-use systems must be guided by a structured approach to E&L risk assessment and CCI evaluations. Following regulatory guidelines and thorough analytical testing will ensure compliance and protect patient safety. Continuous improvement in these evaluation techniques is crucial as new materials and technologies emerge. Remain vigilant and informed to ensure that all practices not only meet but exceed the standards set by regulatory authorities for the pharmaceutical industry.